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Summary
Aptamers (protein binding oligonucleotides) have po-
tential as a new class of targeted therapeutics. For
applications requiring chronic systemic administra-
tion, aptamers must achieve high-affinity target bind-
ing while simultaneously retaining high in vivo sta-
bility, tolerability, and ease of chemical synthesis. To
this end, we describe a method for generating apta-
mers composed entirely of 2-O-methyl nucleotides
(mRmY). We present conditions under which 2-O-
methyl transcripts can be generated directly and use
these conditions to select a fully 2-O-methyl aptamer
from a library of 3 × 1015 unique 2-O-methyl tran-
scripts. This aptamer, ARC245, is 23 nucleotides in
length, binds to vascular endothelial growth factor
(VEGF) with a Kd of 2 nM, and inhibits VEGF activity
in cellular assays. Notably, ARC245 is so stable that
degradation cannot be detected after 96 hr in plasma
at 37°C or after autoclaving at 125°C. We believe
ARC245 has considerable potential as an antiangio-
genesis therapeutic.
Introduction
Aptamers are oligonucleotides that interact highly
specifically with molecular targets such as proteins,
and in this respect are similar to antibodies. Aptamers
are generated using a process called either in vitro se-
lection [1] or SELEX [2]. Over 100 aptamers have been
generated using this process to targets as diverse as
small molecules, peptides, proteins, and whole cells
[3]. Aptamers can be made that specifically and selec-
tively interact with, and often inhibit the function of,
protein targets. There is considerable interest in the use
of aptamers as therapeutics in a manner similar to that
of therapeutic antibodies.
In order for an aptamer to be suitable for use as a
therapeutic it must be inexpensive to synthesize, safe,
and stable in vivo. Wild-type RNA and DNA aptamers
are not stable in vivo because of their susceptibility to
degradation by nucleases. Resistance to nuclease de-
gradation can be greatly increased by the incorporation
of modifying groups at the nucleotide 2# position, and
2#-fluoro- and 2#-amino-substituted libraries have been
successfully used to select partially stabilized apta-
mers [4]. However, these particular modifications in-*Correspondence: keefe@archemix.comcrease the cost of synthesis of the resultant aptamer,
and may introduce safety concerns, as these modified
nucleotides could potentially be recycled into host DNA.
Aptamers that contain 2#-O-methyl (2#-OMe) nucleo-
tides overcome many of these drawbacks. Oligonucle-
otides containing 2#-OMe pyrimidines are nuclease re-
sistant [5] and inexpensive to synthesize. For example,
fully 2#-O-alkylated nucleic acids have been shown to
be completely stable in the rat gastrointestinal tract
over an 8 hr period, in contrast to partially 2#-O-alkyl-
ated nucleic acids [6]. Additionally, 2#-OMe nucleotides
are ubiquitous in biological systems (there are about
100 of these residues in each ribosome [7]). Probably
as a consequence of their presence in biological sys-
tems, natural polymerases do not accept 2#-OMe nu-
cleotide triphosphates (NTPs) as substrates [8], and so
there are no significant safety concerns regarding the
recycling of 2#-OMe nucleotides into host DNA.
There are several examples of 2#-OMe-containing
aptamers in the literature (see, for example, [9]). These
aptamers were generated by the in vitro selection of
libraries of modified transcripts in which the C and U
residues are 2#-fluoro substituted and the A and G resi-
dues are 2#-OH (rRfY). Once functional sequences are
identified, each A and G residue is then tested for its
tolerance of 2#-OMe substitution, and the aptamer is
ultimately synthesized with all A and G residues that
tolerate 2#-OMe substitution as 2#-OMe residues. Most
of the A and G residues of aptamers generated in this
fashion tolerate substitution with 2#-OMe residues, al-
though on average approximately 10%–20% do not.
Consequently, aptamers generated using this method
tend to contain from two to four 2#-OH residues, and
have their stability and cost of synthesis compromised
as a result.
One example of a 2#-OMe-containing aptamer is
Macugen (Pegaptanib sodium) [10] which binds to vas-
cular endothelial growth factor (VEGF). This is an ap-
tamer that is 27 nucleotides long and binds to VEGF
in a calcium-dependent manner with a Kd of 49 pM.
Macugen inhibits the binding of VEGF to its receptors
Flt-1 and KDR. Macugen has successfully completed
phase III clinical trials for wet age-related macular de-
generation and was recently approved for use as a hu-
man therapeutic by the U.S. Food and Drug Administra-
tion (FDA). Macugen was originally selected from a
2#-fluoro pyrimidine, 2#-OH purine (rRfY) library, and
subsequent stabilization efforts successfully replaced
12 of the 14 2#-OH purines with 2#-OMe purines. Macu-
gen is a good example of an aptamer that has its sta-
bility and cost of synthesis compromised as a result of
the fact that it contains two 2#-OH nucleotides. It would
be beneficial if conditions could be found under which
2#-OMe transcripts could be generated enzymatically,
and then reverse transcribed; in this manner, fully 2#-
OMe aptamers (mRmY) could be selected directly.
Recently, two studies have been published that re-
port the discovery of polymerase variants that can in-
corporate 2#-OMe NTPs [11, 12]. Fa et al. report the
directed evolution of a DNA polymerase that can incor-
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26porate up to five dNTPs after a single 2#-OMe NTP, at t
kwhich point polymerization ceases. Chelliserrykattil
tand Ellington report mutants of T7 RNA polymerase
nthat can introduce 2#-OMe A, C, and U into transcripts,
cbut not 2#-OMe G. Unfortunately, neither of these en-
Wzymes can be used to generate fully 2#-OMe (mRmY)
ttranscripts that are long enough to contain aptamers.
u
yResults and Discussion
a
cScreening Polymerases for Production
oof 2-OMe-Containing Transcripts
cIn order to generate libraries of 2#-OMe transcripts, it
Gwas first necessary to find conditions under which a
ptemplate-dependent polymerase would accept 2#-OMe
cNTPs as substrates. The T7 RNA polymerase mutant
GY639F [13] was screened using various combinations
tof concentrations of divalent magnesium and manga-
nese to establish conditions under which transcripts
ocould be produced from solutions containing one 2#-
tOMe NTP and three 2#-OH NTPs. Transcription requires
pthe presence of magnesium, and it is well known that
tthe addition of manganese to the reaction mixes of
eother polymerases can increase their error rates [14].
sDifferent combinations of concentrations of magne-
msium chloride and manganese chloride were investi-
tgated for their effect upon transcription yields. The
ggreatest yields of transcripts were obtained with 5 mM
Omagnesium chloride and 1.5 mM manganese chloride,
oalthough departures from these concentrations of up
lto 2-fold will still give significant amounts of modified
ttranscripts. It should be noted that because NTPs com-
iplex divalent metal ions, the concentration of free metal
aions in solution will be affected by changes in the con-
ccentration of NTPs. The experiments and optimal con-
2centrations of metal ions described here apply to tran-
tscriptions in which each of the four NTPs is at a
tconcentration of 0.5 mM.
GFurther increases in modified transcript yield were
sobserved by priming transcription with either 0.5 mM
u
GMP or guanosine. This effect presumably results from
H
the specificity of the polymerase for the initiating nucle-
otide. Additionally, double-stranded transcription tem- t
plates generated by PCR were found to be greatly t
superior to single-stranded synthetic DNA with a a
double-stranded promoter. Yet further improvements o
were made to the yield of these partially modified tran- t
scripts by including polyethylene glycol (PEG) in the w
transcription mixture. t
s
Improving the Yield of 2-OMe-Containing f
Transcripts e
Transcription can be divided into two phases: initiation “
and elongation [15, 16]. During initiation, GTP (or an- s
other guanosine derivative) is substituted at its 3#-OH n
to yield a dinucleotide and this is then extended by a c
further eight or so nucleotides. During elongation, tran- d
scription proceeds beyond the first 10–12 residues of n
the transcript. There is structural evidence to support a 1
qualitative distinction between the initiation and elon- a
gation phases of transcription [17]. Further consider-
ation of the conformational distinction between the ini- H
dtiation and elongation stages of transcription leads uso consider the utility of a leader sequence. It is well
nown that transcript yields are greatly influenced by
he composition and sequence of the first three to six
ucleotides of the transcript, and that purines, espe-
ially guanosine, are preferred in these positions [18].
e reasoned that the incorporation of 2#-OMe nucleo-
ides into transcripts might be further facilitated by the
se of an all-purine leader sequence that extends be-
ond the point at which the elongation conformation is
chieved at approximately position +10. Large in-
reases in the yields of modified transcript were, in fact,
bserved when the following leader sequence was in-
orporated into the sequence of the DNA template:
GGAGAGGAGAGAA. Using this leader sequence, it is
ossible to produce up to 1 M transcripts in solutions
ontaining only 2#-OMe ATP, UTP, and CTP with 2#-OH
TP (rGmH). Unfortunately, the yields of 2#-OMe G-con-
aining transcripts under these conditions are still low.
We also hypothesized that these successive stages
f transcription were likely to be increasingly insensitive
o the incorporation of 2#-substituted NTPs. For exam-
le, it is known that T7 RNA polymerase is more prone
o incorporate dNTPs once the polymerase is in the
longation phase [19]. Consequently, we hoped that
mall amounts of 2#-OH GTP added to the transcription
ixture would be sufficient to enable the polymerase
o initiate, but that once transcription was in the elon-
ation phase the reduced discrimination between 2#-
Me and 2#-OH GTP, and the excess of 2#-OMe GTP
ver 2#-OH GTP in the transcription mixture, would al-
ow the incorporation of principally 2#-OMe GTP. A titra-
ion of 2#-OH GTP into a transcription mixture contain-
ng only all four 2#-OMe NTPs (r/mGmH) showed up to
10-fold increase in yield of modified transcript as
ompared to the same transcription without any added
#-OMe GTP (data not shown). These results suggest
hat this combination of reaction components results in
he incorporation of significant proportions of 2#-OMe
into transcripts. Ultimately the yields of r/mGmH tran-
cripts were further increased by a factor of five by the
se of the T7 RNA polymerase double-mutant Y639F/
784A [20].
Ultimately, the effect of each of these changes to the
ranscription conditions was assessed by comparing
he yields of r/mRmY transcripts in the presence and
bsence of each change. The double-stranded nature
f the entire transcription template, as opposed to just
he promoter region, and the presence of manganese
ere of critical importance. Their absence decreased
he yield by factors of 200 and 100, respectively. The
hortening of the purine-rich leader sequence from
ourteen to five purines reduced the yield by a factor of
ight and the exclusion of the 30 M 2#-OH GTP
spike” reduced the yield by a factor of ten. The exclu-
ion of PEG and GMP are responsible for relatively mi-
or reductions in r/mRmY transcript yield under the
onditions studied. The yield of r/mRmY transcripts un-
er these optimized conditions is approximately 250
M or 5 g/ml, which is a reduction of approximately
00-fold from an RNA transcription using 2#-OH NTPs
nd wild-type T7 RNA polymerase.
The T7 RNA polymerase double-mutant Y639F/
784A [20] was used for the transcriptions performed
uring SELEX, whereas the T7 RNA polymerase single-
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27Figure 1. Alkaline Hydrolysis Data Demonstrating the Incorporation of 2#-OMe Nucleotides into Transcripts
(A) An alkaline hydrolysis ladder of a 5#-32P-labeled transcript generated by transcription from a mixture containing 2#-OH ATP, CTP, GTP, and
UTP (RNA), each at 0.5 mM, and the single-mutant T7 RNA polymerase Y639F [13]. This ladder shows bands corresponding to all positions
in the transcript.
(B) An alkaline hydrolysis ladder of a 5#-32P-labeled transcript generated by transcription from a mixture containing 2#-OH CTP, GTP, UTP,
and 2#-OMe ATP (rBmA), each at 0.5 mM, and the single-mutant T7 RNA polymerase Y639F. The absence of hydrolysis at positions corre-
sponding to A residues indicates that the transcript contains 2#-OMe A at these positions, and that 2#-OMe nucleotides, within oligonucleo-
tides, are highly resistant to alkaline hydrolysis.
(C) An alkaline hydrolysis ladder of a 5#-32P-labeled transcript generated by transcription from a mixture containing 2#-OH ATP, CTP, and UTP
and 2#-OMe GTP, each at 0.5 mM, and 2#-OH GTP, at 30 M (r/mGmH). Positions corresponding to G residues show greatly reduced intensities
after position +10 (arrow); this observation indicates the incorporation of largely 2#-OMe G residues at G positions once the polymerase has
attained its elongation conformation. The increased intensity of the hydrolysis ladder bands at positions corresponding to G residues at
positions before +10 suggests that the polymerase has a higher discrimination against 2#-OMe GTP before it attains the elongation confor-
mation.
(D) The integrated intensity of the hydrolysis ladder shown in (C). This more clearly shows the difference in intensity between the bands
corresponding to G residues in the initiation and elongation phases of polymerization. Hydrolyses were conducted for 5 min at 95°C in 50
mM Na2CO3 at pH 9.mutant Y639F [13] was used for the transcription opti-
mization work. After the transcription optimization and
SELEX phases of this project had been completed it
was discovered that both the Y639F single-mutant and
Y639F/H784A double-mutant T7 RNA polymerases
used inadvertently additionally contained the K378R
mutation.
Demonstration of 2-OMe Incorporation
We were able to demonstrate that each of 2#-OMe A, C,
and U was being incorporated into modified transcripts
simply by comparing the yield of radiolabeled transcript
([α-32P]GTP was included in the transcription mixture),
as observed by phosphorimaging of a denaturing gel,
in the presence and absence of the nucleotide being
considered (data not shown). Because the transcription
mixtures used to incorporate 2#-OMe G additionally
contained 2#-OH GTP, this approach could not be used
to prove the incorporation of 2#-OMe G. In this in-
stance, a modified transcript of a fixed sequence was
generated from a mixture of 2#-OH ATP, CTP, and UTP
and 2#-OMe GTP, each at 0.5 mM, and 2#-OH GTP, at30 M (r/mGmH). This transcript was 5# end labeled
with 32P and subsequently subjected to partial alkaline
hydrolysis before analysis by denaturing PAGE. A lad-
der of bands was generated in which the intensity of
each band is proportional to the proportion of 2#-OH
nucleotide at the corresponding position in the tran-
script (Figure 1C). Integration of the intensity of each
band clearly shows that up to position +10 in the tran-
script, substantial proportions of 2#-OH G are present
at each G position in the transcript (Figure 1D). After
this point, presumably once the polymerase has transi-
tioned to the elongation conformation, each G in the
transcript is principally 2#-OMe, and as a consequence,
the extent of hydrolysis at each of these positions is
greatly reduced (Figure 1D). An alkaline hydrolysis lad-
der is shown for a transcript generated from a mixture
of 2#-OH CTP, GTP, and UTP and 2#-OMe ATP (rBmA)
(Figure 1B). This image shows the absence of bands
corresponding to A residues in the modified transcript,
thus demonstrating the incorporation of 2#-OMe ATP
into the transcript and the hydrolysis-resistant nature of
2#-OMe nucleotides. Additionally, an alkaline hydrolysis
ladder is shown for a transcript generated from a mix-
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28ture of 2#-OH ATP, CTP, GTP, and UTP (RNA; Figure 1A). l
nThis image shows the presence of bands correspond-
ing to all positions in the sequence. c
DReverse Transcription of 2-OMe-Containing
Transcripts A
AModified transcripts were reverse transcribed using
Thermoscript Reverse Transcriptase (Invitrogen, Grand e
cIsland, NY) at 65°C. Primer extension experiments
showed that the yield of full-length cDNA reverse tran- s
dscribed from a synthetic fully 2#-OMe RNA (mRmY) se-
quence is about 10% of that obtained by the reverse g
ntranscription of the corresponding synthetic DNA (Sup-
plemental Figure S1). This yield is consistent with the f
aobservation that PCR amplification of the resultant
cDNA lagged about four cycles behind the amplifica- t
etion of an equal amount of synthetic DNA (data not
shown). No efforts were made to further increase this (
tyield, and no other reverse transcriptases were assessed
for their ability to reverse transcribe fully 2#-OMe RNA i
m(mRmY). Fully 2#-OMe RNA (mRmY) does not act as a
template for PCR using Taq polymerase and a standard s
sPCR protocol. Also, 2#-OMe NTPs do not act as sub-
strates for DNA synthesis during PCR, nor do they in- v
thibit PCR (data not shown). Transcription with 2#-OMe
ATP, CTP, GTP, and UTP at 0.5 mM and 2#-OH GTP at a
w30 M (r/mGmH) as in Figure 1 gives concentrations of
transcript of approximately 250 nM in the transcription s
smixture after an overnight incubation at 37°C.
The relatively low yields of both the transcription and c
breverse transcription of 2#-OMe RNA lead us to con-
sider that these steps might introduce composition bi- s
iases into libraries of nucleic acids that they act upon.
A secondary concern was that the rate of misincorpora- o
ttion of nucleotides for either process might be too high
for the SELEX process to be able to operate success- j
afully. We examined these concerns by synthesizing
DNA of a fixed sequence, and then subjecting this to t
oPCR amplification to add a T7 promoter and render it
double stranded. This transcription template was then b
atranscribed, DNase treated, reverse transcribed, PCR
amplified, cloned, and sequenced. Transcriptions were s
aperformed both under conditions yielding 2#-OMe
(r/mGmH) and 2#-OH RNA, and the statistics of substi- a
ttutions, deletions, and insertions were compared as
shown in Table 1. The deletion rate for 2#-OMe RNA (r/ s
smGmH) amplification is not higher than for 2#-OH RNA,
but the insertion and substitution rates are higher. a
AThese decreases in fidelity will result in an approxi-
mately 1.5-fold reduction in enrichment rates for an N30 bTable 1. The Fidelity with which Sequence Information Is Transmitted to the Next Generation of Transcripts
Deletions Insertions Substitutions Perfect N30 N
2#-OH RNA 0.7% 0.0% 0.3% 74% 1936 bases
2#-OMe RNA 0.6% 0.6% 1.2% 49% 1584 bases
Sequence data for a single fixed sequence were used to calculate deletion, insertion, and substitution rates after transcription from DNA into
2#-OMe RNA (r/mRmY) using the T7 RNA polymerase single-mutant Y639F [13], reverse transcription into cDNA, and subsequent PCR
amplification. Perfect N30 refers to the probability that a sequence of 30 contiguous positions outside of the designed primer binding regions
is perfectly transmitted to the next generation. Thirty nucleotides was the length of the degenerate region of the library used in this study. N
is the number of nucleotides sequenced. Data for transcription into 2#-OH RNA are shown for comparison. These data are likely to
overestimate error rates because no allowance is made for errors occurring during the sequencing process itself.ibrary during the selection process. This relatively mi-
or reduction in enrichment rate is unlikely to signifi-
antly affect the trajectory of an in vitro selection.
irect Selection of Fully 2-OMe-Modified
ptamers against VEGF
library of 3 × 1014 unique transcription templates,
ach containing a random region of 30 contiguous nu-
leotides, was generated by the PCR amplification of
ynthetic DNA. Cloning and sequencing of this library
emonstrated that the composition of the random re-
ion in this library contains approximately 25% of each
ucleotide (data not shown). This DNA library was puri-
ied away from unincorporated dNTPs by gel filtration
nd ethanol precipitation. Modified transcripts were
hen generated from a mixture containing 0.5 mM of
ach of the four 2#-OMe NTPs and 30 M 2#-OH GTP
r/mGmH). After gel purification and DNase treatment,
hese modified transcripts were dissolved in PBS and
ncubated for 1 hr in an empty well on a hydrophobic
ultiwell plate in an effort to subtract plastic binding
equences. The supernatant solution of modified tran-
cripts was then transferred to a well that had pre-
iously been incubated for 1 hr with VEGF165 (Pepro-
ech, Rocky Hill, NJ) at room temperature in PBS. After
subsequent 1 hr incubation, this well was washed
ith PBS and bound sequences were reverse tran-
cribed in situ using Thermoscript Reverse Tran-
criptase (Invitrogen) at 65°C for 1 hr. The resultant
DNA was then PCR amplified, separated from dNTPs
y gel filtration, and used to generate modified tran-
cripts for input into the next round of selection. An
ndependent initial library of 3 × 1015 synthetic 2#-OMe
ligonucleotides with sequences that correspond to
he library of 2#-OMe transcripts was similarly sub-
ected to a single round of selection and amplification,
nd the two selected libraries were then combined. Af-
er ten rounds of selection and amplification, the ability
f the resultant library to bind to VEGF was assessed
y a nitrocellulose filter binding assay [21] to be 35%
t 64 nM VEGF. At this point, the library was cloned and
equenced and individual clones were assayed for their
bility to bind VEGF. Using a combination of sequence
nd clone binding data, sequence motifs were iden-
ified. These were used to design smaller synthetic con-
tructs of mRmY composition, which were also as-
ayed for binding to VEGF. Ultimately, minimized mRmY
ptamers to VEGF were identified, ARC245 and
RC259, both of which are 23 nucleotides long and
ind VEGF with K values of 2 and 1 nM, respectively,d
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29Figure 2. VEGF Binding Characteristics and Sequences and Puta-
tive Secondary Structures of Aptamers Featured in the Text
All residues are 2#-OMe (mRmY). All constructs were generated by
solid-phase chemical synthesis. These data were generated by nit-
rocellulose filter binding assay [21] in PBS. These data give Kd val-
ues as follows: ARC224, 3.9 nM; ARC245, 2.1 nM; ARC259, 1.4 nM.as measured by nitrocellulose filter binding assay.
ARC259 differs from ARC245 only in the substitution of
an A-U base pair in the terminal stem for a G-C base
pair. ARC224 is an incompletely minimized version of
ARC245 which is 30 nucleotides long and has similar
VEGF binding characteristics. ARC225 has the same
sequence as ARC224, but has seven 2#-OMe G nucleo-
tides replaced by 2#-OH G nucleotides and does not
bind VEGF. Putative secondary structures of these syn-
thetic 2#-OMe aptamers, and their VEGF binding
curves, are shown in Figure 2.
It is not clear whether the observed differences be-
tween the fully 2#-OMe (mRmY) VEGF aptamers discov-
ered in the present study and the 2#-ribo/methyl purine,
2#-fluoro pyrimidine (r/mRfY) VEGF aptamers, including
Macugen, discovered by Ruckman et al. [10] are signifi-
cant. For example, these mRmY aptamers are more
stable, are unusually small, and bind VEGF in a divalent
metal ion-independent manner, while Macugen binds
with a lower Kd value (approximately 50 pM versus ap-
proximately 1 nM) and does so in a calcium-dependentfashion. It is possible that mRmY composition apta-
mers generally bind less well to VEGF than rRfY and
r/mRfY composition aptamers.
Aptamer Tolerance to 2-OH G Substitution
During the selection, modified transcripts were gener-
ated by transcription in the presence of 0.5 mM of each
2#-OMe NTP and additionally 30 M 2#-OH GTP (r/mGmH).
As a consequence, each time selected sequences are
amplified and transcribed for entry into the next round
of selection, a small number of 2#-OH G residues are
incorporated into the modified transcripts in a stochas-
tic fashion. Any selected sequence could therefore, in
principle, be dependent upon the presence of one or
more 2#-OH G nucleotides for VEGF binding. In order
to test the effect of the presence of 2#-OH G residues in
the selected sequence, substitution variants of ARC224
were synthesized in which single 2#-OMe G nucleotides
were substituted by 2#-OH G nucleotides. Each of
these constructs was then assayed for its ability to bind
VEGF by nitrocellulose filter binding. In every instance,
the ability of the 2#-OH-substituted variant to bind
VEGF was inferior to that of fully 2#-OMe ARC224
(mRmY) as shown in Figure 3. In addition, a construct
in which all seven of these nucleotides were simulta-
neously substituted for 2#-OH G nucleotides (rGmH;
ARC225) showed no binding to VEGF at all.
Aptamer Specificity
To explore the specificity of these VEGF aptamers, the
affinity of ARC259 for various related proteins was mea-
sured by nitrocellulose filter binding assay. Murine
VEGF164, which is highly homologous to human
VEGF165, bound ARC259 with the same affinity as hu-
man VEGF165, whereas human VEGF112 and the human
growth factors bFGF, PDGFbb, and PlGF-1 showed no
binding to ARC259 at all. VEGF112 lacks the heparin
binding domain to which ARC259 presumably binds.
Inhibition of VEGF Activity by Fully 2-OMe
Composition Aptamers
In order for an aptamer to have potential therapeutic
utility, it needs to bind to a therapeutic target in a man-
ner that inhibits the function of that target. To assess
whether the synthetic aptamers ARC224 and ARC245
inhibit VEGF activity, two different assays were per-
formed. Initially, the ability of ARC224 to inhibit the
binding of VEGF to VEGF receptors upon the surface
of human umbilical vascular endothelial cells (HUVEC)
was assessed. 125I-labeled VEGF was incubated with
ARC224 and the resultant mixture was then added to
HUVEC; after incubation, the cells were washed and
125I was then counted in a scintillation counter. These
data are presented in Figure 4, which shows that
ARC224 inhibits the binding of VEGF to the HUVEC
VEGF receptors with an IC50 of approximately 2 nM. In
an independent approach to the demonstration of
VEGF inhibition, 293 cells were transfected with a VEG-
FRII (KDR)-encoding plasmid and a KDR-luciferase re-
porting system. Incubating these cells with VEGF in the
presence of ARC224 and ARC245, and assaying for lu-
ciferase using a luminometer, clearly indicates the abil-
ity of these aptamers to bind to VEGF in a manner that
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30Figure 3. VEGF Binding Characteristics of
Various 2#-OH G Variants of ARC224
In each instance, the nomenclature mGXG
indicates the substitution of 2#-OH G for
2#-OMe G at position X numbered from the
5# terminus. ARC225 has the same se-
quence as ARC224 and 2#-OMe to 2#-OH
substitutions at positions 7, 10, 14, 16, 19,
22, and 24 numbered from the 5# terminus.
All constructs were generated by solid-
phase chemical synthesis. These data were
generated by nitrocellulose filter binding [21]
in PBS. The fully 2#-OMe aptamer, ARC224,
has superior VEGF binding characteristics
(lower Kd) when compared to any of the
2#-OH G substitution variants studied here.inhibits its ability to bind KDR at aptamer concentra- s
mtions as low as 10 nM. These data are presented in
Figure 5. a
s
a
nAptamer Stability and Pharmacokinetics
Aptamers that are entirely comprised of 2#-OMe nucle- s
otides (mRmY) are highly resistant to chemical, physi-
cal, thermal, and enzymatic insults. We were unable to S
observe any degradation or decrease in the ability of
synthetic ARC224 to bind to VEGF after exposure to a V
b25 min autoclave cycle with a peak temperature of
125°C (Supplemental Figure S2). The robust nature of d
a2#-OMe aptamers opens up a host of possible applica-
tions for which monoclonal antibodies are not suitable. u
cOne such example is the coating of stents and other
medical devices while retaining the ability to sterilize
the coated device using an autoclave. The nuclease-
resistant nature of these aptamers additionally confers
pharmacokinetic benefits. The clearance half-life of
ARC247 (synthetic ARC245 5# substituted with 40 kDa
poly[ethylene glycol]) and administered to CD-1 mice
intravenously was 23 hr (Figure 6). This compares fa-
vorably with aptamers containing nuclease-susceptible
residues such as 2#-OH and 2#-deoxy that have in vivo
half-lives in the range of 2–10 hr when bearing PEG
groups, and less than 1 hr when not functionalized with
PEG. An in vivo clearance half-life of 23 hr introduces
the possibility of dosing frequencies of once every sev-
eral days.
Partially 2-OMe Aptamers
The nuclease resistance of RNA is greatly increased by
2# substitution at pyrimidine residues [5], although fully
2#-substituted RNA is even more stable. Notably, tran-
scriptions with 2#-OMe CTP, 2#-OMe UTP, 2#-OH ATP, F
hand 2#-OH GTP (rRmY) or 2#-OMe CTP, 2#-OMe UTP,
1
2#-OMe ATP, and 2#-OH GTP (rGmH) give greater yields
tof transcript than transcriptions from mixtures contain-
t
ing all four 2#-OMe NTPs (r/mGmH) (1 M compared to w
250 nM for transcriptions with all four 2#-OMe NTPs T
a[r/mGmH]). We additionally used both of these tran-cription conditions to select partially 2#-OMe apta-
ers to VEGF. Some of these partially 2#-OMe-modified
ptamers have Kd values in the high pM range (data not
hown). However, inclusion of any 2#-OH residues in
n aptamer is likely to increase cost of synthesis, and
egatively impact physical, chemical, and enzymatic
tabilities and pharmacokinetic characteristics.
ignificance
EGF induces angiogenesis [22], the growth of new
lood vessels, and as such is implicated in several
isease states. Early interest focused upon VEGF as
cancer target because tumor growth is consequent
pon angiogenesis and the use of the resultant vas-
ulature for the delivery of nutrients to the tumor.igure 4. ARC245 and ARC259 Bind to VEGF in a Manner that In-
ibits Its Ability to Bind to VEGF Receptors on HUVEC
25I-labeled VEGF was incubated with the synthetic aptamer and
his mixture was then incubated with human umbilical vascular epi-
helial cells (HUVEC). The supernatant was removed, the cells were
ashed, and bound VEGF was counted in a scintillation counter.
hese data indicate that the IC50 values of ARC245 and ARC259
re approximately 2 nM.
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31Figure 5. ARC224 and ARC245 Bind to VEGF in a Manner that In-
hibits Its Biological Function
293 cells were transiently transfected with a VEGFRII (KDR)-
expression plasmid and a KDR-luciferase reporter system. These
data indicate that significant inhibition of KDR occurs as a result of
ARC224 (A) and ARC245 (B) synthetic aptamer concentrationsFigure 6. ARC247 (Synthetic ARC245 5# Substituted with 40 kDa
Polyethylene Glycol) Persists In Vivo in the Blood with a Half-Life
of 23 hr in the Mouse
ARC247 was formulated to 10 mg/ml (oligonucleotide mass) in
0.9% saline and dosed intravenously to ten groups of three CD-1
mice by single bolus injection into the tail vein to 10 mg/kg (oligo-
nucleotide mass). Blood samples were collected at the indicated
time points from groups of three mice and processed into plasma.
Aptamer concentrations in these plasma samples were assessed
by fluorescence of their Oligreen (Molecular Probes) complexes at
520 nm (excitation at 480 nm). Data were processed using WinNon-
Lin v4.0 (Pharsight). ARC247 has a clearance half-life of 23 hr, a
mean residence time of 33 hr, a terminal clearance rate of 0.04 ml/
min/kg, and a volume of distribution at steady state (Vss) of 87
ml/kg. The Vss value suggests a moderate degree of binding or
sequestration of the aptamer to proteins and/or tissue matrix in the
extravascular space.More recently, the utility of VEGF as a therapeutic
target has additionally focused upon other angiogen-
esis disorders such as retinopathy [23, 24] and macu-
lar degeneration, for which an anti-VEGF aptamer
(Macugen) was recently approved by the FDA. Avas-
tin, a humanized anti-VEGF antibody, is also newly
FDA-approved. When administered with a chemother-
apeutic agent, Avastin showed a 50% increase in sur-
vival rate, over the duration of the study, of untreated
metastatic colorectal cancer patients [25, 26]. Angio-
genesis also takes place in other indications such as
psoriasis and rheumatoid arthritis [27]. Inhibitors of
VEGF, therefore, have the potential to act as potent
therapeutics for a range of indications. Aptamers that
function as VEGF inhibitors offer many advantages
as therapeutics, including the fact that they are gener-
ated by chemical synthesis and spontaneously refold
after denaturation. A primary attribute of fully 2-OMe
(mRmY) aptamers is their extreme biological stability.
Additionally, 2-OMe nucleotides do not act as sub-
strates for DNA polymerases [8], and the possibility
of the recycling of 2-OMe nucleotides into host DNA
is not the concern it may be for 2-fluoro nucleotides.
We anticipate that, in addition to VEGF, the selection
methods presented here offer the possibility to gener-as low as 10 nM. ARC225 (C) has the same sequence as ARC224,
but has seven 2#-OMe G nucleotides replaced by 2#-OH G nucleo-
tides and does not bind VEGF.
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tpeutic targets.
s
cExperimental Procedures
e
tMethods
sAll reagents were acquired from Sigma (St. Louis, MO) except
where stated otherwise. VEGF165 was acquired from Peprotech P(Rocky Hill, NJ).
P
2Oligonucleotide Synthesis
YDNA syntheses were undertaken according to standard protocols
pusing an Expedite 8909 DNA synthesizer (Applied Biosystems, Fos-
ater City, CA). The DNA library used in this study had the following
sequence: 5#-CATCGATGCTAGTCGTAACGATCCNNNNNNNNNNN
VNNNNNNNNNNNNNNNNNNNCGAGAACGTTCTCTCTCCCTATAGT
TGAGTCGTATTA-3#, in which N has an equal probability of being
seach of the four nucleotides. Transcription yield optimization and
5fidelity experiments were performed using transcription templates
sprepared by the PCR amplification of the following synthetic DNA
Bsequence: 5#-TAATACGACTCACTATAGGGAGAGGAGAGAACGTTC
sTCGACTGACGTACCACCATCGGATGGTGGAAGATCGAGCTCGAG
KCTAGCTAGCTCTACATCGACTGATCG-3#. 2#-OMe RNA syntheses,
Cincluding those containing 2#-OH nucleotides, were undertaken ac-
acording to standard protocols using a 3900 DNA synthesizer (Ap-
bplied Biosystems). All oligonucleotides were purified by denaturing
uPAGE except PCR and RT primers.
x
a2-OMe Library Generation
The synthetic DNA library (1.5 nmol, 9 × 1014 unique sequences)
Cwas amplified by PCR under standard conditions with the following
Tprimers: 3#-primer CATCGATGCTAGTCGTAACGATCC and 5#-
tprimer TAATACGACTCACTATAGGGAGAGGAGAGAAACGTTCTCG.
VThe resultant library of double-stranded transcription templates
1
was precipitated and separated from unincorporated nucleotides
sby gel filtration. At no point was the library denatured, either by
sthermal means or by exposure to low-salt conditions. Transcription
wwas performed under the following conditions: 200 nM double-
stranded DNA template, 200 mM HEPES, 40 mM DTT, 10% PEG
V8000, 0.01% Triton X-100, 2 mM spermidine, 2#-O-methyl ATP, CTP,
TGTP, and UTP, 0.5 M each (Trilink, San Diego, CA), 30 M 2#-OH
tGTP, 0.5 mM GMP, 5.5 mM MgCl2, 1.5 mM MnCl2, 10 U/ml inorganic
Rpyrophosphatase, 200 nM T7 RNA polymerase double-mutant
wY639F/H784A [20] (pH 7.5), incubated at 37°C overnight. The resul-
(tant transcripts were purified by denaturing 10% PAGE, eluted from
Dthe gel, incubated with RQ1 DNase (Promega, Madison, WI), phenol
Cextracted, chloroform extracted, precipitated, and taken up in
cwater. Transcripts for transcription fidelity and yield optimization
pexperiments were prepared similarly using the following primers:
T3#-primer CGATCAGTCGATGTAGAGCTAGC and 5#-primer TAATAC
eGACTCACTATAGGGAGAGGAGAGAACGTTCTCGACTGACGTAC and
sthe T7 RNA polymerase single-mutant Y639F [13]. After the tran-
ascription optimization and SELEX phases of this project had been
tcompleted, it was discovered that both the Y639F single-mutant
wand Y639F/H784A double-mutant T7 RNA polymerases used addi-
mtionally contained the K378R mutation. For the initiation of selec-
wtion, synthetic 2#-OMe oligonucleotides with sequences that corre-
mspond to the library of 2#-OMe transcripts were additionally
agenerated by the direct chemical synthesis of 2#-OMe RNA; these
were purified by 10% denaturing PAGE.
S
ASELEX
wSelection for VEGF binding aptamers was undertaken using VEGF
Vimmobilized by hydrophobic absorption to the surface of 96-well
Pplates (C96 MaxiSorb 430341, Nalge Nunc, Rochester, NY). VEGF
a(200 nM in 100 l PBS) was incubated in wells for 1 hr at 23°C;
these wells were then washed with PBS six times. 2#-OMe tran-
scripts (1 M in 100 l PBS per well) were incubated in empty wells M
Afor 1 hr at 23°C; the supernatants were then transferred to the
VEGF-containing wells where they were incubated for 1 hr at 23°C. s
iThe supernatants were then removed and discarded, wells were
washed with PBS six times, adherent sequences were reverse tran- g
Bscribed in situ using Thermoscript Reverse Transcriptase (Invitro-en) at 65°C, resultant cDNA was amplified by PCR, and the resul-
ant DNA was used to program a transcription for the subsequent
election step. Round 1 was undertaken separately for syntheti-
ally and enzymatically derived transcripts with 0.6 nmol of unique
nzymatically generated transcripts and 5 nmol of unique synthetic
ranscripts. The corresponding PCR products were transcribed
eparately and combined.
artial Alkaline Hydrolysis
artial alkaline hydrolyses were conducted with trace 5#-32P-labeled
#-OMe transcripts (prepared with T7 RNA polymerase single-mutant
639F [13]) at 95°C in 50 mM Na2CO3 at pH 9 for 5 min in the
resence of 1 mg/ml tRNA. Samples were analyzed by 15% PAGE
nd phosphorimaging.
EGF Binding Assays
he binding of 2#-OMe RNA to purified recombinant VEGF was as-
essed by nitrocellulose filter binding assay [21] in which trace
#-32P-labeled synthetic 2#-OMe RNA was incubated with a dilution
eries of VEGF in 40 l PBS with 0.1 mg/ml tRNA and 1 mg/ml
SA in a silanized plate. This mixture was then passed through a
andwich of a nitrocellulose membrane (Schleicher and Schuell,
eene, NH) over a nylon membrane (Amersham Biosciences, Little
halfont, UK) over Whatman paper (Whatman, Maidstone, UK) on
vacuum manifold, followed by a single wash of 100 l of the
inding buffer. The membranes were phosphorimaged and Kd val-
es were calculated by fitting the resulting data to y = b + c(x/Kd +
), where y is the proportion binding, x is the protein concentration,
nd b and c are dimensionless constants.
ell Surface VEGF Inhibition Assays
he ability of these 2#-OMe aptamers to inhibit the binding of VEGF
o VEGF receptors upon the surface of HUVEC (ATCC, Manassas,
A) was assessed by premixing the synthetic 2#-OMe aptamer with
25I-labeled VEGF (Perkin Elmer, Wellesley, MA), incubating the re-
ultant mixture with HUVEC in MEME (ATCC), washing away the
upernatant, resuspending the cells with SDS/NaOH, and counting
ith a scintillation counter.
EGF Inhibition Assays
he ability of these 2#-OMe aptamers to inhibit the binding of VEGF
o VEGFRII (KDR) was also assessed using the PathDetect Trans-
eporting system (Stratagene, La Jolla, CA) in 293 cells transfected
ith a KDR-expression plasmid. 293 cells (ATCC) were plated
10,000 cells/well) in a 96-well plate and incubated at 37°C in
MEM and 10% FBS (GIBCO, Carlsbad, CA) overnight with 5%
O2. Three plasmids were then transiently transfected into these
ells using FUGENE 6 (Roche, Indianapolis, IN), a KDR-expression
lasmid, pCMV6-XL4-KDR (clone number PR1371_H11; OriGene
echnologies, Rockville, MD; 25 ng/well), an Elk1-dependent lucif-
rase reporter plasmid, pFR-Luc (Roche; 25 ng/well), an Elk-1 fu-
ion protein-expression plasmid, pFA2-Elk1 (Roche; 10 ng/well),
nd a second overnight incubation in Opti-MEM (GIBCO). On the
hird day, the indicated amount of recombinant VEGF premixed
ith the indicated amount of synthetic 2#-OMe aptamer and this
ixture was added to the cells and incubated for 4–6 hr at 37°C
ith 5% CO2. The level of luciferase produced was then deter-
ined with the Steady Glo Luciferase kit (Promega) and immedi-
tely read on a luminometer.
ynthesis of PEG-Aptamer Conjugates
RC247 was prepared by the 5# substitution of synthetic ARC245
ith a hexylamine linker phosphoramidite (Glen Research, Sterling,
A) and the subsequent functionalization of this amine with 40 kDa
EG (Nektar, San Carlos, CA). Both processes were carried out
ccording to the manufacturers’ recommendations.
urine Pharmacokinetics
RC247 (5#-40 kDa PEG-terminated synthetic ARC245) was dis-
olved in 0.9% saline to 10 mg/ml (oligonucleotide mass) and ster-
le filtered through a 0.2 m filter. This solution was dosed to ten
roups of three CD-1 mice to the tail vein by single bolus injection.
lood samples were collected by terminal bleeds into EDTA-coated
Direct Selection of a 2#-O-Methyl Aptamer to VEGF
33tubes at the indicated time points and processed into plasma by
centrifugation at 3000 rpm for 5 min and stored at −80°C until
analysis. Mean aptamer concentrations in these plasma samples
were assessed by fluorescence of their Oligreen (Molecular Probes,
Eugene, OR) complexes after dilution into Tris-EDTA (pH 8) at 520
nm (excitation at 480 nm) by comparison with standard curves.
Data were processed using noncompartmental analysis with Win-
NonLin v4.0 (Pharsight, Mountain View, CA).
Supplemental Data
Supplemental Figures S1–S2 are available at http://www.chembiol.
com/cgi/content/full/12/1/25/DC1/.
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